May 24, 2023
Sagicor Select Fund Manufacturing & Distribution (SELECTMD) for the three months ended March 31, 2023 reported net investment loss of $104.48 million relative to a income of $264.86 million booked March 31, 2022. SELECTMD noted, “This negative performance is due to economic uncertainty globally and rising interest rates.”
This is comprised of:
-
- Interest income which amounted to $2.50 million (2022: $244,000.
- Dividend income which closed at $27.54 million (2022: $27.27 million).
- Net gain in fair value on financial assets at fair value through profit or loss closed at a loss of $134.51 million versus a profit of $237.32 million booked for the comparable period in 2022.
Net foreign currency gains or losses and other income closed the three months period at nil (2022: $21,000).
Total expenses for the three months period closed at $6.70 million, while for the same quarter in 2022, total expenses totalled $8.39 million. Of this, administration expenses equalled $6.70 million, (2022: $8.39 million) for the three months ended March 2023.
Consequently, net loss closed the three months period at $111.18 million, compared to a net profit of $256.47 million reported for the first quarter ended March 31, 2022.
Loss per share for the period under review amounted to $0.03, while for the 2022 first quarter, earnings per share totalled $0.07. The trailing twelve months loss per share amounted to $0.091. The number of shares used in this calculation was 3,816,612,000 shares. SELECTMD price was last traded at a price of $0.56 on May 19, 2023.
Balance Sheet Highlights:
Total assets, as at March 2023, amounted to $3.91 billion (2022: $4.34 billion), a 10% decrease. Of this, Cash and Cash Equivalents closed at $183.12 million (2022: $69.71 million), and ‘Financial assets at fair value through profit or loss’ totalled $3.72 billion (2022: $4.26 billion).
SELECTMD, as at March 31, 2023, booked shareholders’ equity of $3.90 billion versus $4.32 billion booked 2022. Book value per share for the three months amounted to $1.02 (2022: $1.13).
Disclaimer:
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.